Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 6Gastrointestinal 6Other hematologic neoplasm 5Myeloid 5Tumor-Agnostic 2Thoracic 2Head & Neck 2Genitourinary 2Dermatologic 2CNS 2Breast 2Classical hematology 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Antibodies × Tumor-Agnostic × Clear all
NCT02410512 2022-04-01

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
610 enrolled
Tumor-Agnostic

Neoplasms

NCT02458638 2021-06-04

A Study of Atezolizumab in Advanced Solid Tumors

Hoffmann-La Roche

Phase 2 Completed
474 enrolled 14 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡